Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Israeli national security adviser Meir Ben Shabbat U.S. Photo: Mazen Mahdi/Getty Images. U.S. national security adviser Jake Sullivan. Photo: Chandan Khanna/Getty Images

U.S. national security adviser Jake Sullivan spoke on the phone Saturday with his Israeli counterpart Meir Ben Shabbat, Israeli officials tell Axios.

Why it matters: This is the first contact between the Biden White House and Israeli prime minister's office. During the transition, the Biden team refrained from speaking to foreign governments.

Driving the news: Israeli officials said the call was meant mainly as an introduction and to kick off the dialogue.

  • One of the issues discussed was Iran.
  • The two national security advisers also covered the Abraham Accords — the biblical branding the administration has given to the individual normalization agreements between Israel and Bahrain and the United Arab Emirates.
  • In recent days, Sullivan made calls to his counterparts in the U.K., France, Germany, Japan and South Korea.
  • The White House did not comment on the call with the Israeli national security adviser.

The big picture: Israeli Prime Minister Benjamin Netanyahu is concerned about President Biden's stated goal of trying to resume the nuclear deal with Iran. Such a move could result in tensions between the Biden administration and the Israeli government.

  • Secretary of State designate Tony Blinken said at his confirmation hearing this week that "there is a long way" until the Iran deal could be resumed.
  • He stressed that the U.S. will consult with Israel and the Gulf states before making any decisions

Go deeper

Jan 29, 2021 - World

Biden picks Rob Malley as envoy for Iran

Malley (L) during Iran deal negotiations in Vienna, 2015. Photo: Siamek Ebrahimi/Anadolu Agency/Getty Image

Rob Malley will serve as the Biden administration's special envoy for Iran, working out of the State Department, White House press secretary Jen Psaki announced on Friday.

Why it matters: Malley, a former Middle East adviser to Barack Obama, took part in the negotiations over the Iran nuclear deal and is a strong supporter of a U.S. return to the agreement. Reports of his likely selection led to sharp criticism from opponents of the deal like Sen. Tom Cotton (R-Ark.), while former colleagues from the Obama administration rallied to Malley's defense.

Jan 28, 2021 - World

Biden turns the page on Trump's Israel-Palestine policies

Biden with Palestinian President Mahmoud Abbas in 2010. Photo: David Furst/AFP via Getty Images

The Biden administration laid out its Israel-Palestine policy at the UN Security Council on Tuesday, highlighting the importance of repairing ties with the Palestinian Authority.

Driving the news: According to the new policies, the U.S. will resume aid to the Palestinians and reopen the PLO office in Washington and the consulate in Jerusalem.

1 hour ago - Health

CDC panel endorses Pfizer vaccine for 12- to 15-year-olds

Illustration: Brendan Lynch/Axios

An advisory panel for the Centers for Disease Control and Prevention on Wednesday endorsed the Pfizer-BioNTech coronavirus vaccine for 12-to 15-year-olds, following the FDA's emergency use authorization.

Why it matters: Approval from the CDC panel was the final step needed before inoculations could be offered at any vaccination site for this age group.

  • Pfizer has said its vaccine is 100% effective at protecting against COVID-19 in a trial of more than 2,200 children between the ages of 12 and 15.